Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KEYCHAIN: Pembrolizumab vs Cisplatin with Radiotherapy in p16+ HNSCC
NCT03383094Phase 2Active, not recruiting
- Start
- Mar 2018
- Primary completion
- Dec 2026
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of pembrolizumab in head and neck squamous cell carcinoma (HNSCC) (2 arms). Primary endpoint: Progression-Free Survival at 3 years. Started Mar 2018; status: active, not recruiting.
02
Drugs
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NCT03383094.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03383094.